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S U M M A R Y
We report a case of hypersensitivity pneumonitis, possibly due to aerosolized colistin therapy for severe
multi-resistant Gram-negative pneumonia. Microbiological eradication was achieved with colistin
therapy, which was stopped after 12 days in view of rising eosinophilia and possible lung ﬁbrosis. The
eosinophil count started to normalize 3 days after stopping colistin therapy and the patient was
eventually weaned to minimal ventilatory support.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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We report a case of hypersensitivity pneumonitis due to
aerosolized colistin (polymyxin E).
2. Case report
A 69-year-old Indian woman was diagnosed with a localized
perforation of the upper rectum. She underwent a total procto-
colectomy with ileal pouch-anal anastomosis and a defunctioning
loop ileostomy. She had a past medical history of long-standing
ulcerative colitis treated with steroids, diabetes mellitus, and
hyperlipidemia.
Post-operatively, she was admitted to the surgical intensive
care unit (SICU) for septic shock secondary to abdominal wound
infection. During her admission to the SICU, she developed
nosocomial pneumonia secondary to multi-resistant Acinetobacter
baumannii (MRAB), which was only sensitive to gentamicin,
polymyxins, trimethoprim–sulfamethoxazole, and minocycline.
The MRAB pneumonia was treated with nebulized colistin. She
received 1million units (MU) of colistimethate sodium (prodrug of
colistin), initially for 2 days, whichwas increased to 2MU 8-hourly
to facilitate rapid clearance and clinical improvement. During the* Corresponding author. Tel.: +65 63213401; fax: +65 62202780.
E-mail address: andrea.kwa.l.h@sgh.com.sg (A.L. Kwa).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.08.001colistin therapy, the patient was hemodynamically stable without
the need for inotropes. She was also not in overt positive ﬂuid
balance as she was supported with intermittent hemodialysis. A
repeat sputum culture done on day 4 of therapy revealed clearance
of the MRAB. However, a new organism, Stenotrophomonas
maltophilia was isolated instead. This was thought to be a
colonizer, selected out from high-dose nebulized colistin, hence
no treatment was instituted.
On day 5 of the colistin therapy, her ventilatory support
increased signiﬁcantly. Full blood counts (FBC) had also started to
show eosinophilia that had not been present before (Figure 1). A
high-resolution computed tomography (CT) scan of the chest done
on day 9 of nebulized colistin therapy revealed bilateral ground-
glass opacities with increased interstitial lung markings and
patchy air-space opacities, consistent with ﬁbroproliferative
changes on the background of bilateral pneumonia, as reported
by the radiologist.
The high-dose nebulized colistin therapy was stopped after 12
days in view of the rising eosinophilia and possible hypersensitivi-
ty pneumonitis. The eosinophil count started to normalize 3 days
after stopping therapy (Figure 1). Ventilator support was also
decreased and she was eventually weaned to pressure support
mode with minimal pressure support from the ventilator 13 days
after stopping colistin.
During the nebulized colistin therapy, there was concomitant
use of pantoprazole, noradrenaline, soluble insulin, meropenem,
and ﬂuconazole. We performed an extensive literature search andses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Absolute eosinophil count and static lung compliance trends.
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tant medications can cause hypersensitivity pneumonitis or a
similar type of hyper-reactive reaction in the lungs.
Unfortunately, amonth later, she died as a result of a bleed from
the rectal stump.
3. Discussion
The prevalence of multi-drug resistance among Gram-negative
bacteria is rising at an alarming rate, renderingmany antimicrobial
agents ineffective, except polymyxins. Nebulized colistin has been
used successfully for the treatment of respiratory tract infections
due to multidrug-resistant Gram-negative bacilli, with minimal
reported complications.1,2 For our patient, nebulized colistin was
deemed to have successfully eradicated the MRAB by day 4 of
therapy. However, from day 5 onwards, increased ventilatory
requirements were observed. We postulated that this turn of
events was likely due to the development of hypersensitive
pneumonitis as a result of, or exacerbated by, prolonged
nebulization of colistin despite the achievement of early microbi-
ological eradication. This was demonstrated by a sudden increase
in ventilatory requirements during the early course of treatment,
which reduced once colistin was stopped. Airway pressure release
ventilation, an effective safe alternative for difﬁcult-to-oxygenate
patients with acute lung injury/acute respiratory distress syn-
drome (ALI/ARDS), has to be instituted as a result of the increased
ventilatory requirements. We do not think that the increased
ventilatory support was caused by a worsening pneumonia as
there was no progression in the serial chest X-rays or clinically
worsening sepsis as manifested by either a rising white cell count
and/or unstable hemodynamics. Moreover, the increasing trend of
absolute eosinophil counts appeared to correlate with the
increasing ventilatory support, suggesting hypersensitive pneu-
monitis, which we postulate is likely to have been caused by
colistin aerosol therapy. An increased eosinophil count during
polymyxin treatment has previously been reported.3 In addition,
when the Naranjo adverse drug reaction (ADR) probability scale
was applied, the overall score was 7, which means ‘probable’.
Nebulized colistin is often administered in the form of its
prodrug, i.e., colistimethate sodium (previously known as colistin
sulfomethate or colistin sodium). For our patient, we think that thehypersensitivity pneumonitis was due to the conversion of the
prodrug to the biologically active form of colistin. It has been
reported that in a single-dose aerosol exposure, the active colistin
sulfate is much less likely to be tolerated than its prodrug.4 In
water, phosphate buffer, and plasma, there is rapid conversion
from prodrug to colistin within 24 to 48 h at 37 8C.5 After 48 h,
more than 60% of the prodrug is converted to the active form at
37 8C.5
Airway reactivity after colistin aerosol therapy is not uncom-
mon, but this is easily treated with nebulized salbutamol before
colistin aerosol therapy.6 However, McCoy7 reported the develop-
ment of ARDS in a clinically stable cystic ﬁbrosis patient. The
patient developed ARDS after a 5-week old pharmacy-com-
pounded premixed colistin solution was used in his aerosol
therapy. As a result of this fatal episode, the Food and Drug
Administration (FDA) has submitted a warning for this treatment.
In this case, we were unable to ascertain the time interval between
drug reconstitution and nebulization, though in our practice
colistin is usually only reconstituted just prior to administration.
4. Conclusions
We have reported the development of a possible hypersensi-
tivity pneumonitis as a result of high-dose colistin aerosol therapy
in the background of nosocomial pneumonia.
Hence, we recommend that for aerosol therapy requiring
colistin: (1) the prodrug colistimethate sodium should be
reconstituted just before administration in order to avoid excessive
conversion to biologically active colistin, which can cause airway
or alveolar injury; (2) the duration of colistin aerosol therapy for
the treatment of pneumonia due to multidrug-resistant Gram-
negative bacilli may be reduced to less than the recommended 2-
week duration in cases of rapid microbiological eradication.
However, further clinical and pharmacokinetic studies are needed
to prove this.
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